Two new dopamine agonists that are long acting in vivo but short acting in vitro
The effects of two new ergolines, pergolide and CH29-717, on prolactin secretion in vitro and in vivo were compared with those of bromocriptine. Both ergolines had in vitro potencies similar to that of bromocriptine, but had a shorter duration of action. However, in vivo both were longer acting than...
Main Authors: | Grossman, A, Yeo, T, Delitala, G |
---|---|
Format: | Journal article |
Language: | English |
Published: |
1980
|
Similar Items
-
Two new dopamine agonists that are long acting in vivo but short acting in vitro.
by: Grossman, A, et al.
Published: (1980) -
Successful debulking of plurihormonal pituitary macroadenoma with long‐acting pasireotide and dopamine agonist combination therapy
by: Terri W. Jerkins, et al.
Published: (2019-03-01) -
Acute and long-term effects of once-daily oral bromocriptine and a new long-acting non-ergot dopamine agonist, quinagolide, in the treatment of hyperprolactinemia: a double-blind study.
by: Verhelst, J, et al.
Published: (1991) -
Beta-Adrenergic Receptors and Mechanisms in Asthma: The New Long-Acting Beta-Agonists
by: Robert G Townley
Published: (1996-01-01) -
Correction: Cyclopia Extracts Act as ERα Antagonists and ERβ Agonists, In Vitro and In Vivo
Published: (2013-01-01)